Sandoz Group AG (OTCMKTS:SDZNY – Get Free Report) traded up 1% on Thursday . The company traded as high as $42.49 and last traded at $41.71. 19,907 shares traded hands during trading, a decline of 79% from the average session volume of 92,822 shares. The stock had previously closed at $41.31.
Wall Street Analyst Weigh In
A number of equities research analysts recently weighed in on the company. Royal Bank of Canada cut Sandoz Group from a “moderate buy” rating to a “hold” rating in a research note on Monday, September 16th. BNP Paribas downgraded Sandoz Group from a “strong-buy” rating to a “hold” rating in a research report on Monday, December 2nd.
Get Our Latest Stock Report on Sandoz Group
Sandoz Group Stock Performance
Sandoz Group Company Profile
Sandoz Group AG develops, manufactures, and markets generic pharmaceuticals and biosimilars worldwide. The company covers therapeutic areas, including cardiovascular, central nervous system, oncology, infectious diseases, pain and respiratory, diabetes, immunology, endocrinology, hematology, and ophthalmology, as well as bone disease.
See Also
- Five stocks we like better than Sandoz Group
- Market Cap Calculator: How to Calculate Market Cap
- Top 3 Investment Themes to Watch for in 2025
- What is the Australian Securities Exchange (ASX)
- Mega Buybacks in 2025: Why These 3 Leading Stocks Are Buys
- What Is WallStreetBets and What Stocks Are They Targeting?
- AMD vs. NVIDIA: The Better Semiconductor Bet for 2025
Receive News & Ratings for Sandoz Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sandoz Group and related companies with MarketBeat.com's FREE daily email newsletter.